Your shopping cart is currently empty

SEL120-34A HCl is a selective, orally available and ATP-competitive inhibitor of CDK8(CDK8/CycC and CDK19/CycC with IC50s of 4.4 nM and 10.4 nM , respectively), with antitumor activity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $54 | In Stock | In Stock | |
| 5 mg | $128 | In Stock | In Stock | |
| 10 mg | $213 | In Stock | In Stock | |
| 25 mg | $359 | In Stock | In Stock | |
| 50 mg | $533 | - | In Stock | |
| 100 mg | $759 | - | In Stock | |
| 200 mg | $987 | - | In Stock |
| Description | SEL120-34A HCl is a selective, orally available and ATP-competitive inhibitor of CDK8(CDK8/CycC and CDK19/CycC with IC50s of 4.4 nM and 10.4 nM , respectively), with antitumor activity. |
| Targets&IC50 | CDK9-CyclinT:1070 nM (IC50), CDK19-CyclinA:10.4 nM (IC50), CDK8-CyclinC:4.4 nM (IC50) |
| In vitro | SEL120-34A HCl is a selective, ATP-competitive inhibitor of CDK8(IC50 of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively). SEL120-34A HCl is active against a panel of AML cell lines (GI50<1 μM), such as SKNO-1, KG-1, HEL-60, MOLM-16, MV-4-11, OciAML-2, MOLM-6 and OciAML-3 cells, consistent with the effective inhibition range of STAT1 S727 and STAT5 S726. |
| In vivo | The growth of tumor in mice bearing MV4-11 cancer cells inhibited by SEL120-34A (30, 60 mg/kg, p.o.), and also arrests the growth of KG-1-derived tumors at 30 mg/kg via oral administration. |
| Molecular Weight | 450.6 |
| Formula | C15H19Br2ClN4 |
| Cas No. | 1609452-30-3 |
| Smiles | Cl.Cc1c(Br)c(Br)c2CCCn3c(nc1c23)N1CCNCC1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 8.33 mg/mL (18.49 mM), Sonication is recommended. | ||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 0.5 mg/mL (1.11 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.